Roth Capital reiterated their buy rating on shares of Aptose Biosciences Inc. (NASDAQ:APTO) in a report published on Friday. Roth Capital currently has a $8.00 price objective on the stock.

Several other analysts have also recently weighed in on the company. Royal Bank Of Canada restated an outperform rating and set a $23.00 price target on shares of Aptose Biosciences in a report on Saturday, June 25th. Zacks Investment Research cut Aptose Biosciences from a hold rating to a sell rating in a report on Friday, August 12th. RBC Capital Markets reiterated an outperform rating on shares of Aptose Biosciences in a report on Tuesday, September 13th. Finally, Canaccord Genuity reissued a buy rating and issued a $7.00 price target on shares of Aptose Biosciences in a research note on Saturday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $12.30.

Shares of Aptose Biosciences (NASDAQ:APTO) traded down 9.17% during mid-day trading on Friday, hitting $2.18. 35,115 shares of the company were exchanged. The company’s market capitalization is $28.10 million. The firm has a 50 day moving average of $2.22 and a 200 day moving average of $2.47. Aptose Biosciences has a 12-month low of $1.92 and a 12-month high of $6.40.

An institutional investor recently bought a new position in Aptose Biosciences stock. Bank of Montreal Can acquired a new position in Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned 0.43% of Aptose Biosciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.47% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

5 Day Chart for NASDAQ:APTO

Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with's FREE daily email newsletter.